PMV Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $78.6M
- Price
- $1.47
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.00%
- Volume
- 277.3K
About
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
Quick stats
Shares outstanding53.5M
Computed float43.6M
Float / shares81.5%
Cash runway (months)10.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001699382
Websitehttps://www.pmvpharma.com
AI Summary
AI-generated1/11
minorneutralboard change
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a Principal at Samsara BioCapital, to its Board of Directors, adding more than two decades of healthcare investing experience.
The appointment follows completion of enrollment in the Phase 2 monotherapy portion of the pivotal PYNNACLE trial of rezatapopt, with an NDA submission for accelerated approval in TP53 Y220C platinum-resistant/refractory ovarian cancer planned for Q1 2027.
Rezatapopt holds FDA Fast Track and Orphan Drug designations; the board addition is a governance update ahead of the commercialization push rather than a program change.